🕒 Created

The Food and Drug Administration approves Eli Lilly's Mounjaro to reduce heart attack and stroke risks for high-risk adults with Type 2 diabetes.

The Food and Drug Administration approved Eli Lilly's Mounjaro to lower the risk of heart attack and stroke in high-risk adults with Type 2 diabetes. The drug, which also targets GIP and GLP-1 hormone receptors, outperformed its predecessor Trulicity in a large study, showing an 8% lower rate of cardiovascular death, heart attack, or stroke. Eli Lilly researchers stated that the drug is already prescribed for weight loss under the brand name Zepbound. While Mounjaro is now officially recognized for its cardiovascular benefits in diabetic patients, researchers are still gathering data to determine if these same benefits apply to those without diabetes who take Zepbound for weight loss. The approval provides a new option for consumers seeking GLP-1 medications to manage heart health. This development comes as the pharmaceutical industry continues to research next-generation medications, such as retatrutide, which mimics three hormones to achieve weight loss results comparable to surgery.

Sources

Paywall and unreadable sources